In the most recent study, an immunotoxin composed of an anti-Glypican-3 (GPC3) antibody and Pseudomonas aeruginosa exotoxin A (PE38) was designed for the treatment of SCLC and liver cancer. This evidence concerns the gene GPC3 and small cell lung carcinoma.